Effect of dietary monosodium glutamate on trans fat-induced nonalcoholic fatty liver disease

Journal of Lipid Research

Volumn 50, Issue 8, 2009, Pages 1521-1537

  Collison, Kate S ^a   Maqbool, Zakia ^a   Saleh, Soad M ^a   Inglis, Angela ^a   Makhoul, Nadine J ^a   Bakheet, Razan ^a   Al Johi, Mohammed ^a   Al Rabiah, Rana ^a   Zaidi, Marya Z ^a   Al Mohanna, Futwan A ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Free fatty acids; Microsomes; Mitochondria; Peroxisomes; Trans fatty acid; Triglycerides

Indexed keywords

BIOLOGICAL MARKER; FATTY ACID; GLUTAMATE SODIUM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRANS FATTY ACID; TRANSCRIPTION FACTOR; CHOLESTEROL; LIPID; PPARGC1A PROTEIN, MOUSE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE ARREST; CELL DAMAGE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIETARY INTAKE; FATTY ACID BLOOD LEVEL; FATTY ACID OXIDATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEPATITIS; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; INTRAABDOMINAL FAT; LIPID STORAGE; LIPOGENESIS; MALE; MICROARRAY ANALYSIS; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; PERITONEAL CAVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UNINDEXED SEQUENCE; WHITE ADIPOSE TISSUE; ANIMAL; BLOOD; C57BL MOUSE; CELL SIZE; DIET; DNA MICROARRAY; DRUG EFFECT; FAT INTAKE; FATTY LIVER; FEMALE; GENETICS; GLUCOSE BLOOD LEVEL; LIPID METABOLISM; LIVER; METABOLISM; OBESITY; ORGAN SIZE; PATHOLOGY; PREGNANCY;

ADIPOSITY; ANIMALS; BLOOD GLUCOSE; CELL SIZE; CHOLESTEROL; DIET; DIETARY FATS; FATTY LIVER; FEMALE; GENE EXPRESSION REGULATION; INSULIN; INTRA-ABDOMINAL FAT; LEPTIN; LIPID METABOLISM; LIPIDS; LIVER; MALE; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGAN SIZE; PREGNANCY; SODIUM GLUTAMATE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANS FATTY ACIDS; TRANS-ACTIVATORS;

EID: 69449085934     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800418-JLR200     Document Type: Article

References (52)

1. Targher, G. 2007. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet. Med. 24: 1-6.
2. Luyckx, F. H., P. J. Lefebvre, and A. J. Scheen. 2000. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab. 26: 98-106.
3. Solis-Herruzo, J. A., I. Garcia-Ruiz, M. Perez-Carreras, and M. T. MunozYague. 2006. Non-alcoholic fatty liver disease. From insulin resistance to mitochondrial dysfunction. Rev. Esp. Enferm. Dig. 98: 844-874.
4. Cave, M., I. Deaciuc, C. Mendez, Z. Song, S. Joshi-Barve, S. Barve, and C. McClain. 2007. Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J. Nutr. Biochem. 18: 184-195.
5. Dunn, W., and J. B. Schwimmer. 2008. The obesity epidemic and nonalcoholic fatty liver disease in children. Curr. Gastroenterol. Rep. 1: 67-72.
6. Nobili, V., M. Marcellini, R. Devito, P. Ciampalini, F. Piemonte, D. Comparcola, M. R. Sartorelli, and P. Angulo. 2006. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology. 44: 458-465.
7. Yalniz, M., I. H. Bahçecioǧlu, N. Kuzu, S. Celebi, H. Ataseven, B. Ustündag, I. H. Ozercan, and K. Sahin. 2007. Amelioration of steatohepatitis with pentoxifylline in a novel nonalcoholic steatohepatitis model induced by high-fat diet. Dig. Dis. Sci. 52: 2380-2386.
8. USDA Economic Research Service. Dietary Assessment of Major trends in US Food consumption, 1970-2005. http://www.ers.usda.gov/Publications/EIB33/ EIB33_Reportsummary.pdf
9. Osso, F. S., A. S. Moreira, M. T. Teixeira, R. O. Pereira, M. G. Tavares do Carmo, and A. S. Moura. 2008. Trans fatty acids in maternal milk lead to cardiac insulin resistance in adult offspring. Nutrition. 24: 727-732.
10. Saravanan, N., A. Haseeb, N. Z. Ehtesham, and Ghafoorunissa. 2005. Differential effects of dietary saturated and trans-fatty acids on expression of genes associated with insulin sensitivity in rat adipose tissue. Eur. J. Endocrinol. 153: 159-165.
11. Astrup, A., J. Dyerberg, M. Selleck, and S. Stender. 2008. Nutrition transition and its relationship to the development of obesity and related chronic diseases. Obes. Rev. 1 (Suppl.): 48-52.
12. Hirata, A. E., I. S. Andrade, P. Vaskevicius, and M. S. Dolnikoff. 1997. Monosodium glutamate (MSG)-obese rats develop glucose intolerance and insulin resistance to peripheral glucose uptake. Braz. J. Med. Biol. Res. 30: 671-674.
13. de Mello, M. A., C. T. de Souza, L. R. Braga, J. W. dos Santos, I. A. Ribeiro, and C. A. Gobatto. 2001. Glucose tolerance and insulin action in monosodium glutamate (MSG) obese exercise-trained rats. Physiol. Chem. Phys. Med. NMR. 33: 63-71.
14. Matyšková, R., L. Maletínská, J. Maixnerová, Z. Pirník, A. Kiss, and B. Zelezná. 2008. Comparison of the obesity phenotypes related to monosodium glutamate effect on arcuate nucleus and/or the high fat diet feeding in C57Bl/6 and NMRI mice. Physiol. Res. 57: 727-734.
15. Larsen, P. J., J. D. Mikkelsen, D. Jessop, S. L. Lightman, and H. S. Chowdrey. 1994. Neonatal monosodium glutamate treatment alters both the activity and the sensitivity of the rat hypothalamopituitary- adrenocortical axis. J. Endocrinol. 141: 497-503.
16. Nakanishi, Y., K. Tsuneyama, M. Fujimoto, T. L. Salunga, K. Nomoto, J. L. An, Y. Takano, S. Iizuka, M. Nagata, W. Suzuki, et al. 2008. Monosodium glutamate (MSG): a villain and promoter of liver inflammation and dysplasia. J. Autoimmun. 30: 42-50.
17. FAO/WHO. 1974. Toxicological evaluation of certain food additives with a review of general pronciples and of specifications. 17th Report of the Joint FAO/WHO Expert Committee on Food Additives. FAO Nutrition Meetings Report Series no.53, WHO Technical Report Series no. 539.
18. Beyreuther, K., H. K. Biesalski, J. D. Fernstrom, P. Grimm, W. P. Hammes, U. Heinemann, O. Kempski, P. Stehle, H. Steinhart, and R. Walker. 2007. Consensus meeting: monosodium glutamate - an update. Eur. J. Clin. Nutr. 61: 304-313.
19. Yoshida, T., K. Yoshioka, N. Sakane, T. Umekawa, and M. Kondo. 1995. Probucol prevents the progression of fatty liver in MSG obese mice. Exp. Clin. Endocrinol. Diabetes. 103: 119-122.
20. Irizarry, R. A., B. Hobbs, F. Collin, Y. D. Beazer-Barclay, K. J. Antonellis, J. Scherf, and T. P. Speed. 2003. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4: 249-264.
21. Tarling, E., A. Salter, and A. Bennett. 2004. Transcriptional regulation of human SREBP-1c (sterol-regulatory-element-binding protein-1c): a key regulator of lipogenesis. Biochem. Soc. Trans. 32: 107-109.
22. Davis, R. A., J. H. Miyake, T. Y. Hui, and N. J. Spann. 2002. Regulation of cholesterol-7alpha-hydroxylase: BAREly missing a SHP. J. Lipid Res. 43: 533-543.
23. Puri, V., S. Konda, S. Ranjit, M. Aouadi, A. Chawla, M. Chouinard, A. Chakladar, and M. P. Czech. 2007. Fat-specific protein 27, a novel lipid droplet protein that enhances triglyceride storage. Biol. Chem. 282: 34213-34218.
24. Roden, M. 2006. Mechanisms of disease: hepatic steatosis in type 2 diabetes pathogenesis and clinical relevance. Nat. Clin. Pract. Endocrinol. Metab. 2: 335-348.
25. Nwankwo, J. O., A. A. Spector, and F. E. Domann. 2003. A nucleotide insertion in the transcriptional regulatory region of FADS2 gives rise to human fatty acid delta-6-desaturase deficiency. J. Lipid Res. 44: 2311-2319.
26. Deguchi, A., K. Segawa, K. Hosaka, I. B. Weinstein, and K. Umezawa. 2002. Overexpression of phosphatidylinositol synthase enhances growth and G1 progression in NIH3T3 cells. Jpn. J. Cancer Res. 93: 157-166.
27. Larqué, E., P.A. García-Ruiz, F. Perez-Llamas, S. Zamora, and A. Gil. 2003. Dietary trans fatty acids alter the compositions of microsomes and mitochondria and the activities of microsome delta6-fatty acid desaturase and glucose-6-phosphatase in livers of pregnant rats. J. Nutr. 133: 2526-2531.
28. Koh-Banerjee, P., N. F. Chu, D. Spiegelman, B. Rosner, G. Colditz, W. Willett, and E. Rimm. 2003. Prospective study of the association of changes in dietary intake, physical activity, alcohol consumption, and smoking with 9-y gain in waist circumference among 16,587 US men. Am. J. Clin. Nutr. 78: 719-727.
29. Tetri, L. H., M. Basaranoglu, E. M. Brunt, L. M. Yerian, and B. A. Neuschwander-Tetri. 2008. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans-fats and a high fructose corn syrup equivalent. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G987-G995.
30. Deng, Q. G., H. She, J. H. Cheng, S. W. French, D. R. Koop, S. Xiong, and H. Tsukamoto. 2005. Steatohepatitis induced by intragastric overfeeding in mice. Hepatology. 42: 905-914.
31. Kohjima, M., M. Enjoji, N. Higuchi, M. Kato, K. Kotoh, T. Yoshimoto, T. Fujino, M. Yada, R. Yada, N. Harada, et al. 2007. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int. J. Mol. Med. 20: 351-358.
32. Sato, S., H. Shirakawa, S. Tomita, Y. Ohsaki, K. Haketa, O. Tooi, N. Santo, M. Tohkin, Y. Furukawa, F. J. Gonzalez, et al. 2008. Low-dose dioxins alter gene expression related to cholesterol biosynthesis, lipogenesis, and glucose metabolism through the aryl hydrocarbon receptor-mediated pathway in mouse liver. Toxicol. Appl. Pharmacol. 229: 10-19.
33. Nebert, D. W., T. P. Dalton, A. B. Okey, and F. J. Gonzalez. 2004. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J. Biol. Chem. 279: 23847-23850.
34. Shaban, Z., S. El-Shazly, S. Abdelhady, I. Fattouh, K. Muzandu, M. Ishizuka, K. Kimura, A. Kazusaka, and S. Fujita. 2004. Down regulation of hepatic PPARalpha function by AhR ligand. J. Vet. Med. Sci. 66: 1377-1386.
35. Donnelly, K. L., C. I. Smith, S. J. Schwarzenberg, J. Jessurun, M. D. Boldt, and E. J. Parks. 2005. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115: 1343-1351.
36. Kohjima, M., N. Higuchi, M. Kato, K. Kotoh, T. Yoshimoto, T. Fujino, M. Yada, R. Yada, N. Harada, M. Enjoji, et al. 2008. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int. J. Mol. Med. 21: 507-511.
37. Buettner, R., K. G. Parhofer, M. Woenckhaus, C. E. Wrede, L. A. Kunz-Schughart, J. Schölmerich, and L. C. Bollheimer. 2006. Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. J. Mol. Endocrinol. 36: 485-501.
38. Bykov, I., S. Junnikkala, M. Pekna, K. O. Lindros, and S. Meri. 2007. Effect of chronic ethanol consumption on the expression of complement components and acute-phase proteins in liver. Clin. Immunol. 124: 213-220.
39. Liu, H. Y., Q. F. Collins, F. Moukdar, D. Zhuo, J. Han, T. Hong, S. Collins, and W. Cao. 2008. Suppression of hepatic glucose production by human neutrophil alpha-defensins through a signaling pathway distinct from insulin. J. Biol. Chem. 283: 12056-12063.
40. Aranha, M. M., H. Cortez-Pinto, A. Costa, I. B. da Silva, M. E. Camilo, M. C. de Moura, and C. M. Rodrigues. 2008. Bile acid levels are increased in the liver of patients with steatohepatitis. Eur. J. Gastroenterol. Hepatol. 20: 519-525.
41. Kagawa, S., T. Fujiwara, Y. Kadowaki, T. Fukazawa, R. Sok-Joo, J. A. Roth, and N. Tanaka. 1999. Overexpression of the p21 sdi1 gene induces senescence-like state in human cancer cells: implication for senescence-directed molecular therapy for cancer. Cell Death Differ. 6: 765-772.
42. Richardson, M. M., J. R. Jonsson, E. E. Powell, E. M. Brunt, B. A. Neuschwander-Tetri, P. S. Bhathal, J. B. Dixon, M. D. Weltman, H. Tilg, A. R. Moschen, 2007. Progressive fi brosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology. 133: 80-90.
43. van der Poorten, D., K. L. Milner, J. Hui, A. Hodge, M. I. Trenell, J. G. Kench, R. London, T. Peduto, D. J. Chisholm, and J. George. 2008. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology. 48: 449-457.
44. Tchoukalova, Y. D., C. Koutsari, M. V. Karpyak, S. B. Votruba, E. Wendland, and M. D. Jensen. 2008. Subcutaneous adipocyte size and body fat distribution. Am. J. Clin. Nutr. 87: 56-63.
45. Crunkhorn, S., F. Dearie, C. Mantzoros, H. Gami, W. S. da Silva, D. Espinoza, R. Faucette, K. Barry, A. C. Bianco, and M. E. Patti. 2007. Peroxisome proliferator activator receptor gamma coactivator- 1 expression is reduced in obesity: potential pathogenic role of saturated fatty acids and p38 mitogen-activated protein kinase activation. J. Biol. Chem. 282: 15439-15450.
46. Yoneda, M., K. Hotta, Y. Nozaki, H. Endo, T. Uchiyama, H. Mawatari, H. Iida, S. Kato, K. Hosono, K. Fujita, et al. 2008. Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol. 8: 27.
47. Leone, T. C., C. J. Weinheimer, and D. P. Kelly. 1999. A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: the PPARα-null mouse as a model of fatty acid oxidation disorders. Proc. Natl. Acad. Sci. USA. 96: 7473-7478.
48. Sprecher, D. L. 2007. Lipids, lipoproteins, and peroxisome proliferator activated receptor-delta. Am. J. Cardiol. 100: n20-n24.
49. Finck, B. N., M. C. Gropler, Z. Chen, T. C. Leone, M. A. Croce, T. E. Harris, J. C. Lawrence, Jr., and D. P. Kelly. 2006. Lipin 1 is an inducible amplifier of the hepatic PGC-1alpha/PPARalpha regulatory pathway. Cell Metab. 4: 199-210.
50. van Harmelen, V., M. Rydén, E. Sjölin, and J. Hoffstedt. 2007. A role of lipin in human obesity and insulin resistance: relation to adipocyte glucose transport and GLUT4 expression. J. Lipid Res. 48: 201-206.
51. Horton, J. D., I. Shimomura, S. Ikemoto, Y. Bashmakov, and R. E. Hammer. 2003. Overexpression of sterol regulatory element-binding protein-1a in mouse adipose tissue produces adipocyte hypertrophy, increased fatty acid secretion, and fatty liver. J. Biol. Chem. 278: 36652-36660.
52. Chui, P. C., H. P. Guan, M. Lehrke, and M. A. Lazar. 2005. PPARgamma regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1. J. Clin. Invest. 115: 2244-2256.